List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 16 studies with search of:   "Neopharm" [Exact]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
Condition: Neoplasm
Intervention: Drug: Liposome Entrapped Paclitaxel Easy to Use
2 Active, not recruiting IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: Surgery for placement;   Procedure: Radiation therapy;   Drug: Temozolomide with radiation therapy
3 Not yet recruiting Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
Condition: Recurrent Malignant Glioma
Intervention: Drug: IL13-PE38QQR
4 Active, not recruiting Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
Condition: Neoplasm
Interventions: Drug: Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU);   Drug: Paclitaxel for injection (Taxol)
5 Active, not recruiting Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer
Condition: Neoplasms
Intervention: Drug: Liposome-encapsulated SN38
6 Completed Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
Condition: Neoplasms
Intervention: Drug: LErafAON
7 Active, not recruiting Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma;   Malignant Astrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
8 Completed Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors
Condition: Neoplasms
Intervention: Drug: LErafAON
9 Active, not recruiting Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
10 Active, not recruiting Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
Condition: Neoplasms
Intervention: Drug: LErafAON-ETU
11 Terminated Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
Condition: Neoplasms
Intervention: Drug: SS1(dsFv)-PE38
12 Active, not recruiting Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
13 Active, not recruiting The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: IL13-PE38QQR;   Procedure: surgery and catheter placement (2 procedures);   Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer);   Procedure: surgery and wafer placement (1 procedure)
14 Terminated Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Condition: Neoplasms
Intervention: Drug: SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin
15 Active, not recruiting Pre-Operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
16 Completed Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
Condition: Tumors
Intervention: Drug: Liposome Encapsulated Mitoxantrone (LEM)

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services